spacer
home > pmps > autumn 2003 > outsourced development and production; speed in development plus strength in manufacturing equals success in bio/pharma: bio/phardos and bio/pharmos 2004
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Outsourced Development and Production; Speed in Development Plus Strength in Manufacturing Equals Success in Bio/Pharma: Bio/PharDOS and Bio/PharMOS 2004

With the launch of Bio/PharDOS, a new niche event to fill a gap in the market for development outsourcing services across the biotech and pharma value chain, is it time to look at the business prospects for this sector? What are the practical issues to be addressed in taking innovative products from discovery through the development pipeline and into commercial manufacturing? How will these challenges be faced by the industry? When can the market expect to see decent returns? These are weighty issues indeed! Answers are not intuitively obvious; even the sector's analysts are playing a game of 'wait and see' while investors in life science sit on their hands or their wallets waiting for better times ahead.

Judging by the volume of leaflets in the post and any number of emails on the subject of 'pharma outsourcing', one might wonder if this has become the burning 'hot issue' for the industry. It's nonsense of course. Since a golden hey-day, way back in 2000, numerous pharma and biotechnology events have experienced dwindling audiences. Some event organisers, aware of the success enjoyed by specialist, niche shows specifically set up for outsourcing service providers, especially in manufacturing, have tacked the magic 'O' label on to somewhat tired looking events hoping this trick might draw a bigger audience out of the hat. Others have opted to combine or to co-locate different events into a single, 'one-stop shop', primarily as a cost-cutting exercise.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Charles Horth, Life Science Consulting Editor at Cytops

Dr Charles Horth is Life Science Consulting Editor at Cytops, UK. Having gained a PhD in Biochemical Pharmacology, Charles has spent over 30 years in the life science industry after training in biochemistry, medical biochemistry and physiology. His industrial career began with market research in biotechnology, followed by laboratory instrument development. He subsequently worked for Vitamins Research (now part of GSK), CIBA-Geigy in Basel, Switzerland (now Novartis) and Searle, UK (now Pharmacia/Pfizer). Charles helped to set up and market a contract laboratory service for bioanalytical testing, metabolism studies, diagnostics and clinical development services. Charles provides professional advisory services for the pharma, biotech and nutraceuticals sector for a number of European clients. He writes for biotech and pharma publications, has published over 40 scientific articles and was Managing Editor of BioPharmaWeb at VerticalNet Europe and Editor of Life Science Today.

spacer
Dr Charles Horth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement